Literature DB >> 10576767

Acquired lipoprotein lipase deficiency associated with chronic urticaria. A new etiology for type I hyperlipoproteinemia.

A L García-Otín1, F Civeira, J Peinado-Onsurbe, C Gonzalvo, M Llobera, M Pocoví.   

Abstract

Type I hyperlipoproteinemia (type I HLP) is a rare disorder of lipid metabolism characterized by fasting chylomicronemia and reduced postheparin plasma lipoprotein lipase (LPL) activity. Most cases of type I HLP are due to genetic defects in the LPL gene or in its activator, the apolipoprotein CII gene. Several cases of acquired type I HLP have also been described in the course of autoimmune diseases due to the presence of circulating inhibitors of LPL. Here we report a case of type I HLP due to a transient defect of LPL activity during puberty associated with chronic idiopathic urticaria (CIU). The absence of any circulating LPL inhibitor in plasma during the disease was demonstrated. The LPL genotype showed that the patient was heterozygous for the D9N variant. This mutation, previously described, can explain only minor defects in the LPL activity. The presence of HLP just after the onset of CIU, and the elevation of the LPL activity with remission of the HLP when the patient recovered from CIU, indicate that type I HLP was caused by CIU. In summary, we report a new etiology for type I HLP - a transient decrease in LPL activity associated with CIU and with absence of circulating inhibitors. This is the first description of this association, which suggests a new mechanism for type I HLP.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10576767     DOI: 10.1530/eje.0.1410502

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  3 in total

1.  Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome.

Authors:  Ambika P Ashraf; Timothy Beukelman; Valerie Pruneta-Deloche; David R Kelly; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

2.  Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia.

Authors:  Gautamn Sarwal; Ahmad Al-Sarraf; Jiri Frohlich
Journal:  BMJ Case Rep       Date:  2012-11-01

3.  Two cases with transient lipoprotein lipase (LPL) activity impairment: evidence for the possible involvement of an LPL inhibitor.

Authors:  H Nagasaka; H Kikuta; H Chiba; T Murano; H Harashima; A Ohtake; H Senzaki; N Sasaki; I Inoue; S Katayama; K Shirai; K Kobayashi
Journal:  Eur J Pediatr       Date:  2003-01-23       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.